Zoetis Inc. $ZTS Position Lifted by Personal CFO Solutions LLC

Personal CFO Solutions LLC grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 11.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,303 shares of the company’s stock after acquiring an additional 1,044 shares during the period. Personal CFO Solutions LLC’s holdings in Zoetis were worth $1,607,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of ZTS. Brighton Jones LLC raised its stake in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares in the last quarter. PFG Advisors increased its holdings in shares of Zoetis by 28.9% in the 1st quarter. PFG Advisors now owns 9,627 shares of the company’s stock valued at $1,585,000 after acquiring an additional 2,157 shares during the last quarter. SYM FINANCIAL Corp bought a new stake in shares of Zoetis in the 1st quarter valued at approximately $217,000. Wedbush Securities Inc. raised its position in shares of Zoetis by 91.0% during the 1st quarter. Wedbush Securities Inc. now owns 8,173 shares of the company’s stock valued at $1,346,000 after acquiring an additional 3,895 shares in the last quarter. Finally, Pinnacle Associates Ltd. lifted its stake in Zoetis by 12.9% during the first quarter. Pinnacle Associates Ltd. now owns 21,435 shares of the company’s stock worth $3,529,000 after purchasing an additional 2,446 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 1.0%

ZTS stock opened at $115.86 on Friday. The stock has a market cap of $51.06 billion, a PE ratio of 19.94, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The firm’s 50-day simple moving average is $138.28 and its 200 day simple moving average is $150.42. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $181.85. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same quarter in the prior year, the firm earned $1.58 EPS. Zoetis’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.7%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ZTS shares. Morgan Stanley lowered their target price on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a research note on Monday, November 10th. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. UBS Group dropped their price objective on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Argus reissued a “buy” rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Finally, Stifel Nicolaus decreased their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Zoetis has an average rating of “Moderate Buy” and an average price target of $178.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.